ARCTIC: Durvalumab With or Without Tremelimumab as Third-Line or Later Treatment for Metastatic Non-Small Cell Lung Cancer
Annals of Oncology - United Kingdom
doi 10.1016/j.annonc.2020.02.006
Full Text
Open PDFAbstract
Available in full text
Date
May 1, 2020
Authors
Publisher
Elsevier BV